Breaking News Instant updates and real-time market news.

MRK

Merck

$62.77

0.11 (0.18%)

14:33
10/09/16
10/09
14:33
10/09/16
14:33

Merck reports interim KEYNOTE-052 data on Keytruda in urothelial cancer

Merck announced "positive" findings from the phase 2 KEYNOTE-052 study investigating the use of Keytruda in previously untreated patients with unresectable or metastatic urothelial cancer who are ineligible for cisplatin-based therapy. Data presented at the ESMO 2016 Congress showed an overall response rate of 24 percent in the total study population, which included patients with and without PD-L1 expression. Findings presented at ESMO 2016 are from the planned interim analysis of the first 100 patients, which was intended to evaluate ORR and determine the PD-L1-high expression cut-point as examined by expression in tumor and immune cells. Forty-five percent of patients had an Eastern Cooperative Oncology Group Performance Status score of two, 30 percent had a PS score of one, and 24 percent had a PS score of zero. In the total study population, ORR was 24 percent with a complete response rate of six percent. Review of the outcomes based on PD-L1 expression showed that in patients with PD-L1 expression of less than one percent, ORR was 18 percent with a complete response rate of three percent; in patients with PD-L1 expression greater than or equal to one percent and less than 10 percent, ORR was 15 percent with no complete responses; and, in patients expressing PD-L1 at levels equal to or greater than 10 percent, ORR was 37 percent with a complete response rate of 13 percent. Among the 24 percent of patients in the total study population who were responding to treatment, the median duration of response had not been reached -- range 1.4+ to 9.8+ months -- with 83 percent of patients having responses of six months or longer. The safety profile of Keytruda was consistent with that observed in previously reported studies. Five patients discontinued due to a treatment-related adverse event; there were no treatment-related deaths.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

KMB

Kimberly-Clark

$116.09

0.6 (0.52%)

11:26
01/22/18
01/22
11:26
01/22/18
11:26
Technical Analysis
Technical Earnings Preview: Kimberly-Clark in downtrend before news »

The stock has been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

, JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

11:25
01/22/18
01/22
11:25
01/22/18
11:25
Recommendations
Celgene, Juno Therapeutics, Gilead analyst commentary  »

Celgene, Juno deal…

CELG

Celgene

$102.65

0.93 (0.91%)

JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

GILD

Gilead

$80.98

-0.19 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 12

    Feb

  • 16

    Feb

  • 25

    Mar

MOS

Mosaic

$26.40

-0.135 (-0.51%)

11:25
01/22/18
01/22
11:25
01/22/18
11:25
Options
Mosaic call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

LRAD

LRAD Corporation

$2.28

0.02 (0.88%)

11:25
01/22/18
01/22
11:25
01/22/18
11:25
Conference/Events
LRAD Corporation to ho ld a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

11:25
01/22/18
01/22
11:25
01/22/18
11:25
Conference/Events
Board of Governors of the Federal Reserve System holds a closed meeting »

The Board of Governors of…

MCO

Moody's

$158.72

-0.46 (-0.29%)

11:25
01/22/18
01/22
11:25
01/22/18
11:25
Conference/Events
Moody's management to meet with RBC Capital »

RBC Capital Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Feb

$NSD

NASDAQ Market Internals

11:17
01/22/18
01/22
11:17
01/22/18
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$91.66

0.59 (0.65%)

11:16
01/22/18
01/22
11:16
01/22/18
11:16
Technical Analysis
Technical Earnings Preview: Procter & Gamble near life highs before news »

The stock is not far from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

$NYE

NYSE Market Internals

11:16
01/22/18
01/22
11:16
01/22/18
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$55.80

0.63 (1.14%)

11:15
01/22/18
01/22
11:15
01/22/18
11:15
Options
Continental Resources put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
01/22/18
01/22
11:15
01/22/18
11:15
General news
Treasury announced a $35 B 4-week bill offering for Tuesday »

Treasury announced a $35…

11:15
01/22/18
01/22
11:15
01/22/18
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

11:15
01/22/18
01/22
11:15
01/22/18
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

LQ

La Quinta

$20.32

0.135 (0.67%)

, WYN

Wyndham

$126.65

-0.34 (-0.27%)

11:13
01/22/18
01/22
11:13
01/22/18
11:13
Downgrade
La Quinta, Wyndham rating change  »

La Quinta downgraded to…

LQ

La Quinta

$20.32

0.135 (0.67%)

WYN

Wyndham

$126.65

-0.34 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

11:10
01/22/18
01/22
11:10
01/22/18
11:10
Periodicals
KGI's Kuo says Apple will discontinue first-generation iPhone X, MacRumors says »

Apple will discontinue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

11:04
01/22/18
01/22
11:04
01/22/18
11:04
General news
4-Week Bill Announcement Offering Amount data reported »

4-Week Bill Announcement…

ZIOP

Ziopharm

$4.28

-0.08 (-1.83%)

11:02
01/22/18
01/22
11:02
01/22/18
11:02
Periodicals
Ziopharm rise due to 'stupid money' inflow, Feuerstein says »

Adam Feuerstein tweeted:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQ

La Quinta

$20.35

0.17 (0.84%)

11:02
01/22/18
01/22
11:02
01/22/18
11:02
Downgrade
La Quinta rating change  »

La Quinta downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWBI

Northwest Bancshares

$17.09

0.24 (1.42%)

11:01
01/22/18
01/22
11:01
01/22/18
11:01
Earnings
Northwest Bancshares reports Q4 EPS 22c, consensus 22c »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$6.10

-0.34 (-5.28%)

11:01
01/22/18
01/22
11:01
01/22/18
11:01
Hot Stocks
AK Steel: Ladle at Middletown Works caster malfunctioned, no injuries reported »

AK Steel said that on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

XLU

Utilities SPDR

$50.47

0.48 (0.96%)

11:00
01/22/18
01/22
11:00
01/22/18
11:00
Options
Renewed interest in SPDR Utility Fund Mar 49 puts »

Renewed interest in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWBI

Northwest Bancshares

$17.09

0.24 (1.42%)

10:59
01/22/18
01/22
10:59
01/22/18
10:59
Hot Stocks
Northwest Bancshares boosts quarterly dividend 6.25% to 17c per share »

The company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCS

Barclays

$11.61

0.4715 (4.23%)

10:56
01/22/18
01/22
10:56
01/22/18
10:56
Hot Stocks
Barclays: Nehren as head of statistical modeling & development, Equities »

Barclays announces the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALGN

Align Technology

$269.46

-1.24 (-0.46%)

10:55
01/22/18
01/22
10:55
01/22/18
10:55
Options
Align Technology put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

HPQ

HP Inc.

$23.78

0.075 (0.32%)

10:55
01/22/18
01/22
10:55
01/22/18
10:55
Conference/Events
HP Inc. to hold a webcast »

Global Head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.